BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
227.06
-2.05 (-0.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close229.11
Open229.73
Bid225.85 x 800
Ask227.50 x 900
Day's Range225.82 - 230.47
52 Week Range216.12 - 388.67
Volume1,738,935
Avg. Volume2,521,000
Market Cap44.025B
Beta (3Y Monthly)1.73
PE Ratio (TTM)9.81
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters5 hours ago

    Novartis $2 million gene therapy for rare disorder is world's most expensive drug

    ZURICH/NEW YORK, (Reuters) - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. The Food and Drug Administration approved Zolgensma for children under the age of two with SMA, including those not yet showing symptoms. "This is potentially a new standard of care for babies with the most serious form of SMA," said Dr. Emmanuelle Tiongson, a pediatric neurologist at Children's Hospital Los Angeles who has provided Zolgensma to patients under an expanded access programme.

  • Reuters5 hours ago

    For Anderson family, an early bet on SMA gene therapy

    When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy (SMA) as an infant nearly four years ago, his parents Tina and Torence had a decision to make. In years past, many of the babies born with the most severe form of SMA, like Malachi, died before their second birthday. By 2015, drugmakers were testing two experimental therapies in clinical trials: a one-time gene therapy treatment that is now owned by Novartis AG and Spinraza, a Biogen Inc drug which is given through spinal infusion every four months, indefinitely.

  • Novartis Gene Therapy Crosses The $2 Million Mark — Will Others Follow?
    Investor's Business Daily8 hours ago

    Novartis Gene Therapy Crosses The $2 Million Mark — Will Others Follow?

    Novartis stock popped Friday as the Food and Drug Administration approved its gene therapy, Zolgensma, for spinal muscular atrophy treatment, throwing a challenge to Biogen and Ionis.

  • Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval
    American City Business Journals12 hours ago

    Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval

    Biogen has new competition: Swiss pharma giant Novartis received FDA approval Friday for a spinal muscular atrophy drug that can stave off and potentially cure the disease with a single treatment.

  • Biogen Stock One of the Best to Own Next Week
    Schaeffer's Investment Research14 hours ago

    Biogen Stock One of the Best to Own Next Week

    BIIB shares tend to outperform right after Memorial Day

  • Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound?
    Zacks16 hours ago

    Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound?

    Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Preclinical biotech Stoke Therapeutics plans $86M IPO
    American City Business Journalsyesterday

    Preclinical biotech Stoke Therapeutics plans $86M IPO

    An RNA-altering startup led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products is hoping to raise $86 million in an IPO, it disclosed Thursday.

  • Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)
    Zacksyesterday

    Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)

    Let's look at what investors should expect from some of the more notable tech companies still left to report: Veeva Systems Inc. (VEEV), Workday, Inc. (WDAY), and Palo Alto Networks, Inc. (PANW).

  • The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific

    The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific

  • CNBC2 days ago

    The top-performing hedge funds are buying GE, Facebook, Biogen and these other stocks

    Under-the-radar hedge-fund managers beating the market are betting on big comeback stories General Electric and PG&E, as well as Biogen.

  • 3 Tech Stocks for Growth Investors to Buy Right Now
    Zacks2 days ago

    3 Tech Stocks for Growth Investors to Buy Right Now

    Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.

  • Top Research Reports for Chubb, Las Vegas Sands & Biogen
    Zacks2 days ago

    Top Research Reports for Chubb, Las Vegas Sands & Biogen

    Top Research Reports for Chubb, Las Vegas Sands & Biogen

  • Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
    Zacks3 days ago

    Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Dalio’s Bridgewater: Major Stocks Positions and New Buys in Q1
    Market Realist3 days ago

    Dalio’s Bridgewater: Major Stocks Positions and New Buys in Q1

    Can Dalio's Bridgewater Repeat Its Outperformance in 2019?(Continued from Prior Part)BiogenRay Dalio’s Bridgewater Associates made several stock purchases during the first quarter. However, the stock purchases’ size compared to the fund’s ETF

  • Barrons.com3 days ago

    The Best and Worst Big Biotech Stocks, According to One Analyst

    Credit Suisse’s Evan Seigerman gives a thumbs up to Vertex Pharmaceuticals and a thumbs down to Biogen.

  • CNBC3 days ago

    We don't yet have the technology to cure Alzheimer's, health-care investor says

    A long list of companies in the last decade fail to find a treatment for Alzheimer's, including Biogen earlier this year. Conde is speaking on a panel at CNBC's Healthy Returns conference in New York. Biotech companies don't yet have the technology or understanding of Alzheimer's to find a cure for the disease that plagues almost 5.8 million people in the U.S., Andreessen Horowitz general partner Jorge Conde said Tuesday at CNBC's Healthy Returns conference in New York.

  • Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending
    Insider Monkey3 days ago

    Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending

    It's been a rather green day on Wall Street as all three major indexes are positive. The Dow Jones is up over 150 points while the S&P 500 is up 0.84%. Among the stocks traders are watching include Apple Inc. (NASDAQ:AAPL), Biogen Inc. (NASDAQ:BIIB), Amgen, Inc. (NASDAQ:AMGN), Deckers Outdoor Corp (NASDAQ:DECK), and Diamondback Energy Inc (NASDAQ:FANG). Let's analyze why each stock is […]

  • Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer
    Investor's Business Daily4 days ago

    Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer

    Biogen urged shareholders on Monday to reject a mini-tender offer from TRC Capital Corporation for up to 500,000 shares of Biogen stock. The bid is well below market price, Biogen said.

  • MarketWatch5 days ago

    Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital

    Biogen Inc. on Monday advised shareholders to reject a mini-tender offer from TRC Capital which it dismissed as below the market price of its stock. The mini-tender is for the purchase of up to 500,000 shares priced at $216.25. Biogen's stock closed May 10 at $226.23, the last business day before the offer was made, or 4.4% above the offer price, the biotech said in a statement. "Biogen does not endorse TRC Capital's unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to TRC Capital's offer because the offer is at a price below the current market price for Biogen's shares and subject to numerous conditions," the company said. It is not affiliated with TRC, its mini-tender offer or the offer documentation, it added. TRC has made other mini-tender offers, in which it seeks to acquire less than 5% of outstanding shares and avoid the disclosure requirements that a 5% holding brings. "As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under U.S. securities laws," said the statement. Biogen shares were not active premarket, but have fallen 18.2% in the last 12 months, while the S&P 500 has gained 5.4%.

  • Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
    Zacks7 days ago

    Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

    Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.

  • Wayfair cracks Fortune 500 list, joins 15 other Mass. companies
    American City Business Journals8 days ago

    Wayfair cracks Fortune 500 list, joins 15 other Mass. companies

    Wayfair, the Boston-based online furniture retailer, joined the ranks of Massachusetts businesses with a spot on Fortune magazine’s list of 500 of the highest-grossing companies in the United States.

  • Barrons.com9 days ago

    Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks

    The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.

  • CNBC10 days ago

    Stocks making the biggest moves premarket: Alibaba, Zillow Group, Biogen, McDonald's, Beyond Meat & more

    The Chinese e-commerce giant beat estimates by a wide margin on both the top and bottom lines, driven both by increased user engagement and growth in its cloud business. Tilray TLRY — Tilray reported an adjusted quarterly loss of 27 cents per share, two cents larger than analysts were expecting. The Canadian marijuana producer's revenue did come in above estimates, helped by acquisitions, legalization of recreational marijuana use in Canada and growth in its medical markets.

  • Benzinga10 days ago

    The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...

  • 5 Low Price-to-Book Value Stocks for Great Returns
    Zacks10 days ago

    5 Low Price-to-Book Value Stocks for Great Returns

    P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.